Pharma BD Deal Intelligence
Theriva Biologics sold its antibiotic-degrading enzyme portfolio - SYN-004 (ribaxamase), SYN-007 and the SYN-006 carbapenemase candidate - to Biossil under an Asset Purchase and Sale Agreement dated 30 October 2026 and announced 2 November 2026. Theriva received a $350,000 non-refundable upfront payment and is eligible for up to $3 million in regulatory milestones (FDA approval and EMA marketing authorisation) and up to $88 million in cumulative worldwide net sales milestones, plus a low-single-digit running royalty on worldwide net sales capped at $250 million and an uncapped low-double-digit share of certain out-licence consideration. Biossil assumes all future development and commercialisation costs. SYN-004 completed a Phase 2b trial in 412 patients showing protection of the gut microbiome from antibiotic-mediated dysbiosis. The divestiture allows Theriva to concentrate on its oncology programmes. ENTITY NOTE: the SEC filing names the buyer as Biossil Labs Inc., a corporation organised under the laws of Canada; this is recorded against the existing Biossil, Inc. company row (same Toronto AI-native biopharma that acquired ridinilazole from Summit Therapeutics in July 2026). NOTE: ingested at pending_review by bd-enrichment-2026-11-04.
← Browse all deals · How we score deals
More: 2026 deals